Niagen Bioscience, Inc.
Company Stats
- Market Cap
- $231.0M
- as of Sep 30, 2026
- Shares Outstanding
- 79.1M
- Free Float
- 14.6%
Income Statement
- Revenue
- $129.4M
- Operating Income
- $16.3M
- Net Income
- $17.4M
- EBITDA
- $16.9M
- Revenue Growth, 3Y
- 21.6%
Returns & Capital
- Share Repurchases
- $251,000
- SBC, 3Y Avg
- $4.8M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $129.4M | — | — |
| FY2024 | $99.6M | — | — |
| FY2023 | $83.6M | — | — |
| FY2022 | $72.0M | — | — |
| FY2021 | $67.4M | — | — |
Annual filing data through FY ended December 31, 2025; shares and float as of October 28, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back